Last reviewed · How we verify
Enterovirus Type 71 Vaccine
At a glance
| Generic name | Enterovirus Type 71 Vaccine |
|---|---|
| Sponsor | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial (PHASE1, PHASE2)
- Study on the Persistence of Immunity Following EV71 Vaccination
- Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell) (PHASE3)
- Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine (PHASE4)
- A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children (PHASE3)
- A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants (PHASE2)
- A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants (PHASE1)
- Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |